ArticleIranian journal of public health2025
Effect of I Quit Ordinary Smoking (IQOS) Use on Hepcidin and Iron Parameters in Comparison with Conventional Smoking.
Article in Iranian journal of public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: IQOS (I Quit Ordinary Smoking) has been introduced as a "safer" alternative to traditional tobacco smoking. We aimed to determine how heated tobacco products influence iron metabolism by examining the impact of IQOS use and conventional cigarette smoking on hepcidin and iron-related parameters. Methods: In this cross-sectional study, an iron panel and hepcidin levels were measured in participants who were using IQOS for at least six months and compared with those of conventional smokers or non-smokers. Results: A total of 185 adults (18-40 years) of both sexes participated in the study, including 80 IQOS users, 49 cigarette smokers and 56 non-smokers. No significant differences were found in hemoglobin level, red blood cell count, mean corpuscular volume, white blood cell count, platelet count or total iron level between IQOS users and non-smokers in both sexes. However, ferritin levels were significantly higher in male IQOS users compared to non-smokers ( Conclusion: IQOS use was associated with significantly elevated hepcidin levels and higher ferritin in males, suggesting a potential disruption of iron regulation compared to conventional smokers and non-smokers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.